Talazoparib and Olaparib are both oral PARP inhibitors that interfere with the PARP enzyme, making it more difficult for cancer cells with BRCA1 or BRCA2 mutations to repair DNA damage, reducing the likelihood of cancer survival and progression (D’Andrea, 2018; Slade, 2020). Here, BRCA1 is linked to cancer.